Germany Approves Trial of Pfizer and BioNTech’s COVID-19 Vaccine
Germany has approved a phase 1/2 clinical trial of Pfizer and BioNTech’s COVID-19 vaccine candidate – the first COVID-19 vaccine trial to be approved in the country.
The trial will include 200 healthy subjects between ages 18 and 55. The drugmakers also plan on conducting a trial in the U.S. upon regulatory approval.
Pfizer and BioNTech are jointly developing four vaccine candidates as part of BioNTech’s BNT162 COVID-19 program.